Lactobacillus acidophilus L-92
What does the research say about Lactobacillus acidophilus L-92?
14 health outcomes synthesisedLactobacillus acidophilus L-92 is a probiotic strain that has been studied across 14 health outcomes, with research most consistently supporting its role in reducing inflammation and atopic dermatitis severity. The strongest evidence comes from 9 studies on inflammation (moderate evidence strength, small effect size) and 6 studies on atopic dermatitis severity (moderate evidence, moderate effect size), largely in children and adults with these conditions. Notably, one study specified a dose of 20 mg per day for atopic dermatitis, though dosing information is frequently absent across the broader literature.
Strongest evidence
Research on Lactobacillus acidophilus L-92 is strongest for reducing inflammation (moderate evidence, 9 studies) and reducing atopic dermatitis severity (moderate evidence, 6 studies). For inflammation, all 9 studies reported beneficial effects, with the largest analysis (n=3390) in type 2 diabetes patients showing small reductions in C-reactive protein and TNF-alpha. For atopic dermatitis, 4 of 6 studies found statistically significant moderate improvements in severity scores (e.g., SCORAD), primarily in children and adults with clinical atopic dermatitis. A related outcome—improved atopic dermatitis severity (SCORAD)—also shows moderate evidence from 4 studies, all beneficial, with one study using 20 mg/day of L-92.
Mixed or weaker evidence
Several outcomes have low or very low evidence strength. Improved immune function (12 studies) and reduced allergic symptoms (11 studies) show consistently beneficial directions, but most studies are reviews, few reached statistical significance, and effect sizes are small to moderate. Improved gut microbiota balance (6 studies) and improved gut health (5 studies) have very low evidence, relying entirely on review articles with no original clinical trial data and no reported doses or durations. Glycemic control (3 studies) is supported only by reviews and indirect fermentation studies, with the one significant trial using a multi-strain product, not L-92 alone.
Effective dose patterns
Dosing information is sparse across the literature. The only specific dose reported is 20 mg/day of heat-killed and dried L-92 in one atopic dermatitis study. Most studies (across inflammation, immune function, allergic rhinitis, and gut health outcomes) did not report dose, form (live vs. heat-killed), or treatment duration, making it impossible to identify a consistent dose range from the current evidence.
Population insights
The clearest population patterns emerge for inflammation (type 2 diabetes patients, underweight individuals) and atopic dermatitis (children and adults with clinical disease). For allergic symptoms, populations studied include people with cedar pollen allergy, allergic rhinitis, and atopic dermatitis. Notably, no evidence identifies elderly, deficient, or specific responder subgroups—most studies focus on symptomatic clinical populations.
Notable caveats
Across all outcomes, the research faces publication bias (beneficial results are more likely to be published). For many outcomes, the evidence base is small (often 4–12 studies) and consists largely of review articles rather than primary randomized controlled trials. Statistical significance is frequently not reached, suggesting true effects may be smaller than the direction implies. Doses, durations, and probiotic form (live vs. heat-killed) are inconsistently reported, limiting practical guidance.
Frequently asked
What is Lactobacillus acidophilus L-92 good for according to research?
Research most consistently supports L-92 for reducing inflammation (9 studies, moderate evidence, small effect) and reducing atopic dermatitis severity (6 studies, moderate evidence, moderate effect). Weaker but still positive evidence exists for improving immune function, reducing allergic symptoms, and improving gut health, though these findings are more preliminary and often based on review articles rather than direct clinical trials.What dose of Lactobacillus acidophilus L-92 is typically used in studies?
Only one study specified a dose: 20 mg per day of heat-killed and dried L-92 for atopic dermatitis. Across almost all other outcomes—inflammation, immune function, allergic rhinitis, gut health—doses were not reported. This makes it impossible to determine a typical or effective dose range from the current evidence.Who benefits most from Lactobacillus acidophilus L-92?
The strongest evidence identifies benefits in specific clinical populations: people with type 2 diabetes and underweight individuals for reducing inflammation, and children and adults with atopic dermatitis for reducing skin severity scores. For allergic symptoms, studies included people with cedar pollen allergy and allergic rhinitis. No research identifies general healthy populations as primary beneficiaries.Are there caveats or limitations in the research on Lactobacillus acidophilus L-92?
Yes. The evidence across nearly all outcomes is subject to publication bias—studies with positive results are more likely to be published. Many outcomes are supported only by small numbers of studies (often 3–12) that are review articles, not original clinical trials. Statistical significance is frequently not reached, meaning effects may be smaller than observed direction suggests. Doses, durations, and whether the probiotic is live or heat-killed are often not reported, limiting practical conclusions.Does Lactobacillus acidophilus L-92 help with atopic dermatitis?
The evidence is moderately strong for atopic dermatitis. All 6 studies on reducing severity reported beneficial effects (4 statistically significant), with a moderate effect size. Two additional studies on improving atopic dermatitis symptoms (SCORAD scores) also showed significant benefits. Most evidence comes from children and adults with clinical atopic dermatitis, with one study using 20 mg/day of heat-killed L-92.Does Lactobacillus acidophilus L-92 improve immune function?
Data is limited. While all 12 studies reported beneficial effects on immune function, the evidence strength is low. Only 1 small randomized trial (n=50) found statistically significant results, and most studies were reviews. The predominant effect size is small, and no dose or duration information was consistently reported, making the evidence preliminary rather than conclusive.
- Moderate evidenceReduced Inflammation
- Moderate evidenceReduced Atopic Dermatitis Severity
- Moderate evidenceImproved Atopic Dermatitis Severity
- Low evidenceImproved Immune Function
- Low evidenceReduced Allergic Symptoms
- Low evidenceReduced Severity of Allergic Rhinitis Symptoms
- Low evidenceImproved Immune Modulation
- Low evidenceImproved Allergic Symptoms
- Low evidenceImproved Atopic Dermatitis Symptoms
- Low evidenceImproved Glycemic Control